A Phase II Clinical Trial of Carbon-ion Radiotherapy for Locally Advanced Pancreatic Cancer - Carbon-ion radiotherapy for pancreatic cancer (iROCK-1702PA)

Kanagawa Cancer Center, Kanagawa Prefectural Hospital Organization0 个研究点目标入组 30 人开始时间: 2018年1月12日最近更新: 2024年4月1日

试验速览

This study confirmed safety and efficacy comparable to those reported from prior facilities.

•1) Patient with direct invasion in the gastrointestinal tract which fulfills either following conditions; (a) Endoscopic findings of obvious invasion in stomach and duodenum (b) Imaging findings, including those by computed tomography, of invasion inside the gastrointestinal tract 2) Obvious peritoneal dissemination, except for small amount of ascites or negative cytology of ascites 3) Gastric or duodenal ulcer, except for ulcer scar 4) Metallic stent for occlusive jaundice 5) Open injury or active and intractable infection in the target lesion 6) Severe complications such as severe cerebrovascular disease, intractable diabetes, severe cardiovascular disease, angina, myocardial infarction within 3 months from the onset, severe liver dysfunction, severe psychiatric disease if concomitant radiochemotherapy is selected, Severe complication which influences irradiation of carbon-ion beam such as psychiatric disease if carbon-ion radiotherapy alone is selected 7) Active and untreated double cancer, except for intraepithelial carcinoma, intramucinous carcinoma or malignancy controlled for a long-term 8) Medically or psychologically unsuitable conditions

发起方

Kanagawa Cancer Center, Kanagawa Prefectural Hospital Organization